NCT06486948

An Exploratory, Double-arm, 8-week Study to Explore the Feasibility and Acceptability of Abbreviated Treatment with CT-156 in People with Schizophrenia.

A Multicenter, Exploratory, Randomized, Double-Arm, 8-week Study to Evaluate the Feasibility and Acceptability of an Abbreviated Treatment with CT-156 in People with Schizophrenia

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 58 (actual)
• Sponsor: Click Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

An exploratory, double-arm, 8-week study to explore the feasibility and acceptability of abbreviated treatment with CT-156 for people with Schizophrenia.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DEVICE	CT-156	CT-156 is a digital therapeutic (DTx) under development to treat patients 18 years of age and older with a diagnosis of schizophrenia under standard of care therapy who are on antipsychotic medication and not currently experiencing acute hallucinations or delusions.

Timeline

• Start date: 2024-05-06
• Primary completion: 2024-08-09
• Completion: 2024-08-09
• First posted: 2024-07-05
• Last updated: 2025-01-09

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study